



Software for
Business Intelligence

BizInt Smart Charts

Patents & IP Sequences | Clinical Trials | Drug Pipelines

Support your IP Analysis with BizInt Smart Charts for Patents

II-PIC 2017

John Willmore, Vice President & Founder

2 November 2017, Bengaluru, India

www.bizint.com

20 Years of BizInt Solutions

- Small software company founded in 1996.
- BizInt Smart Charts for Patents released in 1998.
- Windows software to build reports from your search results.

BizInt has moved to Seattle in the Pacific NW



BizInt Smart Charts

Patents & IP Sequences | Clinical Trials | Drug Pipelines

takes your search results

Pretium - laculis Bidendum (last updated 2012-11-17)
Accession Number: 0000186077
Indication: Phospho, Furo, Moxa, Phena
Therapeutic Class (WHO): Humani factus laculis dolo
Therapeutic Class (GAMA): Nihilam perferentia
Originator: (S)gnis condendum comelle (S)gnis
Other Companies: (L)gryps turps (sed utriusq)
Last Update: 2012-11-17
Accession Number: 0000186077
Confidence Rating: (S)gnis
Higest Phase: Phase II
Drug Development (Phase Extended)
Indication Phase Route Country
Phospho Phase II OP (S)gnis
Furo Phase I OP Phocor
Moxa Phena Phase II OP Sollen

Toror Fells - Nunc (last updated 2011-05-03)
Accession Number: 00017041982
Indication: Conus, Nihilam
Therapeutic Class (WHO): Con, acumense
Therapeutic Class (GAMA): Sollen
Originator: (S)gnis condendum comelle (S)gnis
Other Companies: (L)gryps turps (sed utriusq)
Last Update: 2011-05-03
Accession Number: 00017041982
Confidence Rating: (S)gnis
Higest Phase: Phase II
Drug Development (Phase Extended)
Indication Phase Route Country
Conus Phase II OP (S)gnis
Sollen Phase I OP (S)gnis

Etiam Mollis - Aenean (last updated 2012-01-13)
Accession Number: 0000001860180
Indication: Pheno, Bilibio, Libio
Therapeutic Class (WHO): Dolo, variis acis
Therapeutic Class (GAMA): Nihilam, perferentia
Originator: (S)gnis condendum comelle (S)gnis
Other Companies: (L)gryps turps (sed utriusq)
Last Update: 2012-01-13
Accession Number: 0000001860180
Confidence Rating: (S)gnis
Higest Phase: Phase II
Drug Development (Phase Extended)
Indication Phase Route Country
Pheno Phase I OP Phocor
Bilibio Phase 2 OP Phocor
Libio Phase 3 OP Sollen

Consectetur Sitae (last updated 2012-03-01)
Accession Number: 00000008900
Indication: Phospho, Furo, Ane
Therapeutic Class (WHO): Humani factus laculis dolo
Therapeutic Class (GAMA): Nihilam perferentia
Originator: (S)gnis condendum comelle (S)gnis
Other Companies: (L)gryps turps (sed utriusq)
Last Update: 2012-03-01
Accession Number: 00000008900
Confidence Rating: (S)gnis
Higest Phase: Phase II
Drug Development (Phase Extended)
Indication Phase Route Country
Phospho Phase II OP (S)gnis
Furo Phase I OP Phocor
Ane Phase I OP Sollen



...and automatically builds tabular reports.

Integrating results from different databases.

	Drug	Common Drug Name	Database	Synonyms	Highest Phase	Companies	Last Update
1		Pretium					
2	Pretium XGS	Pretium	Loreet Sem	Varius auctor Diam gravida XS-2	Phase2	Labortis Turpis Aliquam Sodales	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue dui	Phase 3	Egestas Conditum Labortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elifend-UR	Quam diam Augue dui Aenean id lectus	Phase 3	Egestas Conditum	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loreet Sem	Adiscing Poin Mattis Faucibus laculus	Phase 3	Conditum Erat	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elifend-UR	Adiscing Et Sec Poin Mattis Faucibus	Phase 2	Conditum Erat	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenead lectus purus Nulla sit amet Quisque placerat 2A	Phase 2	Loareet	2011-06-03
8	Toror Felis III	Toror Felis	Loreet Sem	Aenead lectus purus Quisque placerat	Phase 2	Loareet	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non uma Ligula est Quam sem ac	Phase 3	Labortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non uma Ligula est Quam sem ac	Phase 3	Labortis turpis	2012-03-01

Pretium – laculis Bibendum (adiscing est) Donec

Last Update: 2012-11-17
Accession Number: 002075041982

Indication: Phasus, Ficus, Amet
Therapeutic Class (WHO): Nullam faucibus laculis dolor
Therapeutic Class (EMA): Nullam perleretque

Originator: (Spiras condimentum condisit) (Bismarck)

Other Companies: (Loaret) (Sodales)

Last Update: 2012-11-17
Accession Number: 002075041982
Confidence Rating: (Sodales)

Highest Phase: Phase 3

Drug Development (Phase Extended)

Indication	Phase	Route	Country
Phasus	Phase 3	OP	Phasus
Ficus	Phase 1	OP	Phasus
Mauris Phasus	Phase 3	OP	Sodales

Last Phase Change: 2011-09-20

Properties

Mechanism of Action: Suspend condimentum ligula est

Route of Administration: OP

Commercial Introduction

Laculis auctor ferrem qua magna. Etiam mollis perum anu...
Varying...
Originator: (Spiras condimentum condisit) (Bismarck)

Toror Felis – Nunc (mollis) Donec

Last Update: 2011-06-03
Accession Number: 002075041982

Indication: Condisit
Therapeutic Class (WHO): Condisit
Therapeutic Class (EMA): Condisit

Originator: (Spiras condimentum condisit) (Bismarck)

Other Companies: (Loaret) (Sodales)

Last Update: 2011-06-03
Accession Number: 002075041982
Confidence Rating: (Sodales)

Highest Phase: Phase 3

Drug Development (Phase Extended)

Indication	Phase	Route	Country
Condisit	Phase 3	OP	Phasus
Sodales	Phase 3	OP	Phasus

Last Phase Change: 2010-12-20

Properties

Mechanism of Action: Suspend condimentum ligula est

Route of Administration: OP

Commercial Introduction

Aenead lectus purus...
Originator: (Spiras condimentum condisit) (Bismarck)

Etiam Mollis – Aenean (adiscing est) Donec

Last Update: 2012-01-13
Accession Number: 002075041982

Indication: Phasus, Bibendum, Liberos
Therapeutic Class (WHO): Condisit
Therapeutic Class (EMA): Condisit

Originator: (Spiras condimentum condisit) (Bismarck)

Other Companies: (Loaret) (Sodales)

Last Update: 2012-01-13
Accession Number: 002075041982
Confidence Rating: (Sodales)

Highest Phase: Phase 3

Drug Development (Phase Extended)

Indication	Phase	Route	Country
Phasus	Phase 3	OP	Phasus
Bibendum	Phase 2	OP	Phasus
Liberos	Phase 3	OP	Phasus

Last Phase Change: 2011-01-20

Properties

Mechanism of Action: Suspend condimentum ligula est

Route of Administration: OP

Commercial Introduction

Condisit...
Originator: (Spiras condimentum condisit) (Bismarck)

Consectetur (sodales) Donec

Last Update: 2012-03-01
Accession Number: 002075041982

Indication: Phasus, Ficus, Amet
Therapeutic Class (WHO): Nullam faucibus laculis dolor
Therapeutic Class (EMA): Nullam perleretque

Originator: (Spiras condimentum condisit) (Bismarck)

Other Companies: (Loaret) (Sodales)

Last Update: 2012-03-01
Accession Number: 002075041982
Confidence Rating: (Sodales)

Highest Phase: Phase 3

Drug Development (Phase Extended)

Indication	Phase	Route	Country
Phasus	Phase 3	OP	Phasus
Ficus	Phase 1	OP	Phasus
Amet	Phase 3	OP	Sodales

Last Phase Change: 2010-02-21

Properties

Mechanism of Action: Suspend condimentum ligula est

Route of Administration: OP

Commercial Introduction

Laculis auctor ferrem qua magna. Etiam mollis perum anu...
Originator: (Spiras condimentum condisit) (Bismarck)

Reports integrating key IP data...

CAS-9 - GenomeQuest, PatBase, DWPI (new STN), FAMPAT

Title	Database	Patent Family			Family Status				Probable Assignee	Sequence Locations									
		Patent	Kind	Date	Pub No.	State	Status	Expiry		Seq. ID Number	% Identity	Length	Location						
1. Altering a target nucleic acid in a cell by introducing into the cell a first foreign nucleic acid encoding guide RNA sequences complementary to DNA, and introducing into the cell a second foreign nucleic acid encoding a Cas9 protein	1.1 DWPI	US20150140664	A1	20150521	WO 201577290	ALIVE	PENDING	2034-11-19	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US20150140664-0001	100.00	1368	probable disclosure (not found by automated parsing)	1.2					
	1.2 GPATPRT link	WO2015077290	A2	20150528	A2														
	1.3 Patbase link	WO2015077290	A3	20150806	US	ALIVE	PENDING	2034-06-30											
	1.4 FAMPAT link				20150140664 A1														
<div style="display: flex; justify-content: space-between; margin-top: 10px;"> 1.1 DWPI 1.1 DWPI 1.4 FAMPAT 1.3 Patbase </div>																			
2. New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	2.1 DWPI	WO 15070193	A1	2015-05-14	WO 201570193	ALIVE	PENDING	2034-11-11	RADIANT GENOMICS INC	US20150132263-0002	100.00	1368	claim: 19; 20	2.3					
	2.2 DWPI	US 2015132263	A	2015-05-14	A1														
	2.3 GPATPRT link	US 2015353901	A	2015-12-10	US	ALIVE	PENDING	2034-11-11											
	2.4 GPATPRT link				20150132263 A1														
	2.5 Patbase link				US	ALIVE	PENDING	2034-11-11											
	2.6 FAMPAT link				20150353901 A1														
<div style="display: flex; justify-content: space-between; margin-top: 10px;"> 2.1 DWPI 2.5 Patbase 2.6 FAMPAT 2.5 Patbase </div>																			
3. Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein	3.1 DWPI	US 2014356959	A	2014-12-04	US	ALIVE	PENDING	2034-06-04	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US20140356959-0001	100.00	1368	probable disclosure (not found by automated parsing)	3.3					
	3.2 DWPI	US 2014356956	A	2014-12-04	20140356956 A1														
	3.3 GPATPRT link	AU 2014274939	AA	2014-12-11	US 9267135 B2	ALIVE	GRANTED	2034-06-04											
	3.4 GPATPRT link	WO 14197568	A2	2014-12-11															
	3.5 Patbase link	WO 14197568	A3	2015-03-12															
	3.6 FAMPAT link	CA 2914638	AA	2015-12-04															
<div style="display: flex; justify-content: space-between; margin-top: 10px;"> 3.1 DWPI 3.5 Patbase 3.6 FAMPAT 3.5 Patbase </div>																			

from patent databases...

CAS-9 - GenomeQuest, PatBase, DWPI (new STN), FAMPAT

	Title	Database	Patent Family			Family Status			
			Patent	Kind	Date	Pub No.	State	Status	Expiry
1.	Modulating expression of a target nucleic acid comprises providing to the cell a guide RNA including a transcriptional activator or repressor domain as a fusion protein, and providing to the cell a nuclease null Cas9 protein	1.1 DWPI	US 2014356959	A	2014-12-04	US	ALIVE	PENDING	2034-06-04
		1.2 DWPI	US 2014356956	A	2014-12-04	20140356956 A1			
		1.3 GPATPRT link	AU 2014274939	AA	2014-12-11	US 9267135 B2	ALIVE	GRANTED	2034-06-04
		1.4 GPATPRT link	WO 14197568	A2	2014-12-11				
		1.5 Patbase link	WO 14197568	A3	2015-03-12				
		1.6 FAMPAT link	CA 2914638	AA	2015-12-04				
			KR 20160014036	A	2016-02-05				
2.	New bacteriophage comprises polynucleotide expressing RNA-directed DNA-binding polypeptide comprising nuclease module, and targeting module comprising guide RNA, for restricting growth of host cell, and for preparing antiseptic composition	2.1 DWPI	WO 15070193		2015-05-14	WO 201570193	ALIVE	PENDING	2034-11-11
		2.2 DWPI	US 2015132263	A	2015-05-14	A1			
		2.3 GPATPRT link	US 2015353901	A	2015-12-10	US	ALIVE	PENDING	2034-11-11
		2.4 GPATPRT link				20150132263 A1			
		2.5 Patbase link				US	ALIVE	PENDING	2034-11-11
		2.6 FAMPAT link				20150353901 A1			




...and IP sequence databases.

Probable Assignee	Sequence Locations			
	Seq. ID Number	% Identity	Length	Location
PRESIDENT AND FELLOWS OF HARVARD COLLEGE	US20140356959-0001	100.00	1368	probable disclosure (not found by automated parsing) 1.3
	US20140356956-0001	100.00	1368	probable disclosure (not found by automated parsing) 1.4
1.5 Patbase				
RADIANT GENOMICS INC	US20150132263-0002	100.00	1368	claim: 19; 20 2.3
	US20150353901-0002	100.00	1368	claim: 19; 20 2.4
2.5 Patbase				






Top Assignees (PatBase) by Therapy (DWPI)



vantage point
Smart Charts Edition

Summary Record export with hit structures

3. Title: Boron-containing small molecules		
Basic Patent Number: CA 2810021 A1		
Inventor(s): Hernandez, Vincent S.; Ding, Charles; Plattner, Jacob J.; Alley, Michael Richard Kevin; Rock, Fernando; Zhang, Suoming; Easom, Eric; Li, Xianfeng; Zhou, Ding		
Patent Assignee: Anacor Pharmaceuticals, Inc., United States (US)		
International Patent Class: A61K0031/69; A61P0031/04; C07F0005/02		
CA Classification: Organometallic And Organometalloidal Compounds (29)		
Hit Structures:		
<p>1364682-96-1</p> <p>1-Propanol, 3-[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)</p>	<p>CM1 CRN 1364682-95-0</p> 	<p>Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)</p> <p>prepn. of benzoxaborole derivs. useful for treating bacterial infections</p>
	<p>CM2 CRN 76-05-1</p> 	
<p>1364683-03-3</p> <p>1-Propanol, 3-[[3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, hydrochloride (1:1)</p>	 <p>• HCl</p>	<p>Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)</p> <p>prepn. of benzoxaborole derivs. useful for treating bacterial infections</p>





BizInt Smart Charts

VERSION

4

for Patents

Patent Databases

Provide data on patents filed worldwide

- STN - Classic (including **STNext**) & New STN
- Questel Orbit.com (including **FULLPAT**)
- Minesoft PatBase
- Innovation, Cortellis IP, Integrity Patents
- LexisNexis TotalPatent
- GQ LifeSciences LifeQuest



BizInt Smart Charts

VERSION

4

for Patents

IP Sequence Databases

Provide data on sequences filed in patents

- GenomeQuest (Geneseq, GQ-PAT)
- STN (USGENE, DGENE, PCTGEN)



BizInt Smart Charts

VERSION

4

for Patents

Literature Databases

Provide data on technical and scientific publications

- **Biomedical** (Embase, Biosis, Medline)
- **Scientific** (SciSearch, Chemical Abstracts, PQSciTech, etc)
- **Technical** (INSPEC, RAPRA, GEOREF, etc.)
- **Hosts:** STN (Classic & New), ProQuest Dialog, Ovid, PubMed

Orbit.com: Improved Family Status table and Key Content

Title	Family Status				Object of Invention	Advantages / Drawbacks
	Pub No.	State	Status	Expiry		
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation	WO201493635A1	DEAD	LAPSED	2015-06-12	<p>[0009] In one aspect, the invention provides methods for using one or more elements of a CRISPR system.</p> <p>[0011] Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also provided are the same for use in gene or genome editing. Also provided is use of the same in the manufacture of a medicament for gene or genome editing, for instance treatment by gene or genome editing. [CONT.]</p>	<p>These are advantageous as when singly mutated they provide nickase activity and when both mutations are present the Cas9 is converted into a catalytically null mutant which is useful for generic DNA binding.</p> <p>[0025] It will be appreciated that the terms Cas and CR ISPR enzyme are general!)? [CONT.]</p>
	WO201493635A1	ALIVE	PENDING	2033-12-12		
	US20140186919A1	ALIVE	PENDING	2033-12-12		
	US88865406B2	ALIVE	GRANTED	2033-12-12		
	US8889418B2	ALIVE	GRANTED	2033-12-12		
	US20140335620A1	ALIVE	GRANTED	2033-12-12		
	EP2898075A1	ALIVE	GRANTED	2033-12-12		
	JP2016501532A	ALIVE	PENDING	2033-12-12		
	AU2013359212A1	ALIVE	PENDING	2033-12-12		
	IL239315A	ALIVE	PENDING	2033-12-12		
	SG11201504519TA	ALIVE	PENDING	2033-12-12		
	KR20150105634A	ALIVE	PENDING	2033-12-12		
	CN105209621A	ALIVE	PENDING	2033-12-12		
HK1207119A1	ALIVE	GRANTED	2033-12-12			
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)	WO2015138510A1	ALIVE	PENDING	2035-03-10	<p>In another aspect, disclosed herein is a nucleic acid, e.g., an isolated or nonnaturally occurring nucleic acid, e.g., DNA, that comprises (a) a sequence that encodes a gRNA molecule comprising a targeting domain that</p>	<p>Unilateral subretinal injections of adeno-associated virus particles carrying constructs encoding the wild- type RPE65 cDNA were shown to be safe and moderately effective in some patients, without causing any adverse effects.</p>
	US20150252358A1	ALIVE	PENDING	2035-03-10		

Family Status table
(including Kind Code)

Orbit.com: FULLPAT support including top line legal status

FULLPAT: fullpat_sample

	Title	Questel Family ID	Patent Family			Status Details			
			Patent	Kind	Date	Pub No.	State	Status	Expiry
1	Methods and compositions for target detection in a nanopore using a labelled polymer scaffold	74634926	WO2016187159	A2	2016-11-24	WO 2016187159 A2	ALIVE	PENDING	2018-11-15
			WO2016187159	A3	2016-12-29				
2	Delivery system for functional nucleases	68771523	US20150071906	A1	2015-03-12	US 9526784 B2	ALIVE	GRANTED	2034-08-18
			US9526784	B2	2016-12-27				
3	Efficient non-meiotic allele introgression	68723127	US20150067898	A1	2015-03-05	US 9528124 B2	ALIVE	GRANTED	2034-10-09
			US9528124	B2	2016-12-27				
4	Cell cycle dependent genome regulation and modification	74986865	WO2016210271	A1	2016-12-29	WO 2016210271 A1	ALIVE	PENDING	2018-12-24

Status Details table
(like Family Status)

Orbit.com: FULLPAT includes status details for all EP member states

Status Details			
Pub No.	State	Status	Expiry
EP2727848A1	ALIVE	GRANTED	2032-06-22
AT	ALIVE	GRANTED	2032-06-22
CH	ALIVE	GRANTED	2032-06-22
DE	ALIVE	GRANTED	2032-06-22
EP2957508	DEAD	LAPSED	2016-06-24
GB	ALIVE	GRANTED	2032-06-22
GR	DEAD	LAPSED	2017-04-28
IE	ALIVE	GRANTED	2032-06-22
LT	DEAD	LAPSED	2017-03-10
LV	DEAD	LAPSED	2017-02-28
NL	DEAD	LAPSED	2016-11-09
NO	DEAD	LAPSED	2017-04-28
SE	DEAD	LAPSED	2017-04-28

PatBase: Dead or Alive status



	Title	Patent Family			Family Status		State
		Patent	Kind	Date	Pub No.	State	
1	Gyroscopic space ship/station with docking mechanism	WO 9819911	A2	1998-05-14	WO 9819911 A2	ALIVE	ALIVE
		WO 9819911	A3	1998-07-09	WO 9819911 A3	ALIVE	
		US 6045094	A	2000-04-04	US 6045094 A	DEAD	
		CA 2268724	AA	2000-10-14	CA 2268724 AA	DEAD	
		CA 2268724	C	2007-10-30	CA 2268724 C	DEAD	
		JP 2001524044	T2	2001-11-27	JP 2001524044 T2	DEAD	
		JP 4026840	B2	2007-12-26	JP 4026840 B2	ALIVE	
2	De-orbit instrument package	CA 2365758	AA	2002-06-20	CA 2365758 AA	DEAD	ALIVE
		US 2002109047	A	2002-08-15	US 2002109047 A	ALIVE	
		US 2004124313	A	2004-07-01	US 2004124313 A	ALIVE	
		US 6869048	BB	2005-03-22	US 6869048 BB	ALIVE	

Dead or Alive at the Publication level

... and at the Family level.

Derwent Innovation: Family State, Estimated expiry, relevancy

Status Details			DWPI Family State	Est. Expiry Date	Est. Expiry Date Factors	Est. Remaining Life	Relevancy
Pub No.	State	Expiry					
US 9661011	Alive	2026-07-21	Alive	2026-07-21	Est. Earliest Eff. Filing Date: 2006-03-10 35 USC Patent Term Adjustment: 133	3317 Days (9 Years, 1 Months)	null



- Family State for INPADOC and DWPI families
- Estimated Expiry Date w/ justification

PatBase: selection of relevant claims

	Title	Patent Family			Claims
		Patent	Kind	Date	
1	A METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY	AU 2014273082	AA	2014-12-04	WO14191518A1 CLAIMS 1. A method for precisely inducing a nucleic acid cleavage in a genetic sequence in a cell comprising: (a) Selecting a first and second double-stranded nucleic acid targets in said genetic sequence, each nucleic acid targets comprising, on one strand, a PAM motif at one 3' extremities; [CONT.]
		WO 14191518	A1	2014-12-04	
		CA 2913865	AA	2015-11-27	
2	GENOME ENGINEERING	WO 15013583	A2	2015-01-29	US2015031132A 1. A method of altering target DNA in a stem cell expressing a Cas 9 enzyme that forms a co-localization complex with a guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner comprising (a) introducing into the stem cell a first foreign nucleic acid encoding the guide RNA complementary to the target DNA and which guides the enzyme to the [CONT.]
		WO 15013583	A8	2015-03-05	
		WO 15013583	A3	2015-04-23	
		US 2015031132	A	2015-01-29	
		US 2015031132	A	2015-01-29	
		AU 2014293015	AA	2015-01-29	
		CA 2918540	AA	2016-01-15	
3	METHODS FOR CORRECTING CASPASE-9 POINT MUTATIONS	WO 15089406	A1	2015-06-18	US9068179B 1. A method of editing a nucleic acid molecule encoding a Presenilin1 (PSEN1) protein, the method comprising contacting the nucleic acid molecule with (a) a fusion protein comprising a nuclease-inactive Cas9 domain and a deaminase domain; and (b) a single guide RNA (sgRNA) targeting the fusion protein of (a) to the PSEN1-encoding nucleic acid molecule; [CONT.]
		US 2015166985	A	2015-06-18	
		US 2015166984	A	2015-06-18	
		US 2015166983	A	2015-06-18	
		US 2015166982	A	2015-06-18	
		US 2015166981	A	2015-06-18	
		US 2015166980	A	2015-06-18	
		US 2015165854	A	2015-06-18	
		US 9068179	B	2015-06-30	

PatBase & Orbit: Abstract and Claims source document identified

	Title	Database	Patent Family			Abstract	Claims
			Patent	Kind	Date		
1	PROCESSED EDIBLE PRODUCT COMPRISING A POLYELECTROLYTE COMPLEX AND AN ANTIMICROBIAL COMPOUND	PatBase	WO 15034360	A1	2015-03-12	Source: WO15034360A1 The invention related to a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation. The invention further relates to a method for producing a processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation, [CONT.]	WO15034360A1 Claims 1. A processed edible product comprising a complex of at least one antimicrobial compound and a polyelectrolyte complex of a polyanion and a polycation.
2	Method and system for controlling a cutting torch	FAMPAT	WO 201182492 US 20130221585 US 9011758	A1 A1 B2	2011-07-14 2013-08-29 2015-04-21	(WO201182492) A system for controlling a temperature of a flame of a torch for cutting a piece of material, comprising: a valve system fluidly connectable to an oxygen source and a fuel source for receiving a heating oxygen flow and a fuel flow, respectively, and the torch for propagating the heating oxygen and fuel flows thereto, the valve system comprising at least a first adjustable valve and [CONT.]	(WO201182492) 1. A system for controlling a temperature of a flame of a torch for cutting a piece of material, comprising: a valve system fluidly connectable to an oxygen source and a fuel source for receiving a heating oxygen flow and a fuel flow, respectively, and the torch for propagating the heating oxygen and fuel flows thereto, the valve system comprising at least a first adjustable valve [CONT.]

Index terms

Hit Index Terms table in the chart

Improved Index Terms display in the records




Hit Index Terms		
RN	Role	Notes
1655492-02-6P	Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN)	prepn. and biol. applications of tricyclic benzoxaborole compds.
1364682-96-1P 1364683-03-3P	Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)	prepn. of benzoxaborole derivs. useful for treating bacterial infections
1364684-69-4P 1364684-75-2P	Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN)	prepn. of benzoxaborole derivs. useful for treating bacterial infections

Index Terms

1364682-96-1P 1364683-03-3P RL: Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES) (prepn. of benzoxaborole derivs. useful for treating bacterial infections)

1364684-69-4P 1364684-75-2P RL: Preparation (PREP); Reactant (RCT); Reactant or Reagent (RACT); Synthetic Preparation (SPN) (prepn. of benzoxaborole derivs. useful for treating bacterial infections)




Support for hit structures in summary records

3. Title: Boron-containing small molecules		
Basic Patent Number: CA 2810021 A1		
Inventor(s): Hernandez, Vincent S.; Ding, Charles; Plattner, Jacob J.; Alley, Michael Richard Kevin; Rock, Fernando; Zhang, Suoming; Easom, Eric; Li, Xianfeng; Zhou, Ding		
Patent Assignee: Anacor Pharmaceuticals, Inc., United States (US)		
International Patent Class: A61K0031/69; A61P0031/04; C07F0005/02		
CA Classification: Organometallic And Organometalloidal Compounds (29)		
Hit Structures:		
<p>1364682-96-1</p> <p>1-Propanol, 3-[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)</p>	<p>CM1 CRN 1364682-95-0</p>  <p>CM2 CRN 76-05-1</p> 	<p>Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)</p> <p>prepn. of benzoxaborole derivs. useful for treating bacterial infections</p>
<p>1364683-03-3</p> <p>1-Propanol, 3-[[3-(aminomethyl)-4-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, hydrochloride (1:1)</p>	 <p>• HCl</p>	<p>Biological Study (BIOL); Pharmacological Activity (PAC); Preparation (PREP); Synthetic Preparation (SPN); Therapeutic Use (THU); Uses (USES)</p> <p>prepn. of benzoxaborole derivs. useful for treating bacterial infections</p>

- New STN - now
- Classic STN - later this year

This fall: Structure-oriented table

Index of Hit Structures

	SUBSTANCE	STRUCTURE	REFERENCE
1	<p>1655492-02-6</p> <p>2,1-Benzoxaborole, 4-fluoro-1,3-dihydro-1-hydroxy-3-(nitromethyl)-7-[2-(phenylmethoxy)ethoxy]-</p>		<ul style="list-style-type: none"> • prepn. and anti-mycobacterial activity of benzoxaborole compds. Reference 1 • prepn. and biol. applications of tricyclic benzoxaborole compds. Reference 2
2	<p>1364682-96-1</p> <p>1-Propanol, 3-[[3-(aminomethyl)-4-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:2)</p>	<p>CM1 CRN 1364682-95-0</p>  <p>CM2 CRN 76-05-1</p> 	<ul style="list-style-type: none"> • prepn. of benzoxaborole derivs. useful for treating bacterial infections Reference 3

Drug Development Suite



- **Drug Pipeline databases:**
 - Citeline Pharmaprojects
 - Clarivate Cortellis
 - Adis R&D Insight
 - IMS R&D Focus
 - Clarivate Integrity
- **Clinical Trial databases:**
 - Registries:** ClinicalTrials.gov, EudraCT, WHO ICTRP
 - Commercial:** Citeline Trialtrove, Adis Clinical Trials Insight, Cortellis Trials Intelligence



Software for
Business Intelligence

BizInt Smart Charts

**Come talk with us
in the exhibit hall!**

bizint.com/Cookbook

www.bizint.com